SCHEMBL6924980

SCHEMBL6924980

Fc1ccc(-c2c[nH]c(-c3ccnc(N4CCN(CCC5CC5)CC4)c3)n2)cc1F

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 7/20 0.42
DRD3 P35462 6/20 0.42
DRD4 P21917 3/20 0.42
PIK3C3 Q8NEB9 1/20 0.41
RPS6KB1 P23443 1/20 0.39
AKT1 P31749 1/20 0.39
HTR1A P08908 2/20 0.38
HTR2A P28223 2/20 0.38
HTR2C P28335 2/20 0.38
HTR7 P34969 2/20 0.38
SLC6A4 P31645 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
KCNH2 Q12809 1/20 0.37
ITGB2 P05107 1/20 0.37
ICAM1 P05362 1/20 0.37
ITGAL P20701 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6925244 0.92 PIK3C3 (0.43) DRD2DRD3DRD4PIK3C3HTR1A
SCHEMBL6927297 0.91 DRD2 (0.43) DRD2DRD3DRD4PIK3C3HTR1A
SCHEMBL6924877 0.90 PIK3C3 (0.38) PIK3C3RPS6KB1AKT1KCNH2
SCHEMBL6921703 0.87 LRRK2 (0.43) PIK3C3RPS6KB1AKT1KCNH2ITGB2
SCHEMBL6927914 0.87 TRPV3 (0.43) PIK3C3RPS6KB1AKT1KCNH2ITGB2
SCHEMBL6927205 0.85 KCNH2 (0.40) DRD2PIK3C3HTR2AKCNH2ITGB2
SCHEMBL6925150 0.83 WNT1 (0.42) PIK3C3KCNH2ITGB2ICAM1ITGAL
SCHEMBL6922166 0.82 PIK3C3 (0.40) DRD2DRD3DRD4PIK3C3
SCHEMBL6926804 0.82 TRPA1 (0.39) DRD2DRD3DRD4HTR1AHTR2A
SCHEMBL6924977 0.80 TLR9 (0.41) PIK3C3KCNH2ITGB2ICAM1ITGAL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6355635-B1 IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY PFIZER INC. 2002-03-12 US claimed
US-20010039277-A1 Compounds for the treatment of obesity ELLIOTT RICHARD L (US) 2001-11-08 US claimed
WO-2000066578-A1 COMPOUNDS FOR THE TREATMENT OF OBESITY PFIZER PRODUCTS INC. (US) 2000-11-09 WO claimed
US-6514966-B2 Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine PFIZER INC. 2003-02-04 US disclosed
US-6355635-B1 IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY PFIZER INC. 2002-03-12 US disclosed
US-20010039277-A1 Compounds for the treatment of obesity ELLIOTT RICHARD L (US) 2001-11-08 US disclosed
WO-2000066578-A1 COMPOUNDS FOR THE TREATMENT OF OBESITY PFIZER PRODUCTS INC. (US) 2000-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010039277-A1 Compounds for the treatment of obesity NPY1R, NPY4R, NPY2R DRD2 1447/4885DRD3 1478/4885DRD4 2672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.